p53 expression in squamous dysplasia associated with carcinoma of the oesophagus: evidence for field carcinogenesis

被引:41
作者
Yasuda, M
Kuwano, H
Watanabe, M
Toh, Y
Ohno, S
Sugimachi, K
机构
[1] Fukuoka Dent Coll Hosp, Dept Surg, Sawara Ku, Fukuoka 8140193, Japan
[2] Gunma Univ, Sch Med, Dept Surg 1, Maebashi, Gumma 3718511, Japan
[3] Kyushu Univ, Fac Med, Dept Surg 2, Higashi Ku, Fukuoka 8128582, Japan
关键词
dysplasia; oesophagus; p53; immunohistochemistry; field carcinogenesis; prognosis;
D O I
10.1054/bjoc.2000.1443
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Squamous epithelial dysplasia is often observed multifocally in the cancerous oesophagus and is presumably considered to be a pre-cancerous lesion, A mutation of the p53 tumour suppressor gene is commonly identified in oesophageal cancer and dysplasia. p53 mutations can be anticipated immunohistochemically. In order to confirm the biological and clinical significance of p53 expressions in oesophageal field carcinogenesis, immunostaining for p53 in cancerous and muitifocal precancerous lesions from resected human oesophagus was systematically investigated, while paying special attention to the contiguity of these lesions. Lesions expressing p53 were detected in 46.5% (20 of 43 lesions) of the invasive carcinoma, and in 51.0% (46 of 90 lesions) of the carcinoma in situ, and in 51.4% (92 of 179 lesions) of the dysplasia. Next, the p53 expression in dysplasia was compared with that in carcinoma for the same case. 37 of 39 (94.8%) dysplasias contiguous to p53-positive carcinomas also expressed p53 (P < 0.0001), On the other hand, the isolated dysplasias without contiguity to p53-positive carcinomas, only expressed p53 protein in 44.0% (11 of 25 lesions). No significant correlations were found between the p53 staining and either the clinicopathological features or prognosis. Discordant p53 alterations, such as those seen in cancerous and isolated precancerous lesions, may thus demonstrate further evidence for a multicentric or field carcinogenesis of the human oesophagus. (C) 2000 Cancer Research Campaign.
引用
收藏
页码:1033 / 1038
页数:6
相关论文
共 42 条
[1]  
BENNETT WP, 1991, ONCOGENE, V6, P1779
[2]  
BENNETT WP, 1992, CANCER RES, V52, P6092
[3]   DEGRADATION OF NUCLEAR ONCOPROTEINS BY THE UBIQUITIN SYSTEM INVITRO [J].
CIECHANOVER, A ;
DIGIUSEPPE, JA ;
BERCOVICH, B ;
ORIAN, A ;
RICHTER, JD ;
SCHWARTZ, AL ;
BRODEUR, GM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (01) :139-143
[4]   ACTIVATING MUTATIONS FOR TRANSFORMATION BY P53 PRODUCE A GENE-PRODUCT THAT FORMS AN HSC70-P53 COMPLEX WITH AN ALTERED HALF-LIFE [J].
FINLAY, CA ;
HINDS, PW ;
TAN, TH ;
ELIYAHU, D ;
OREN, M ;
LEVINE, AJ .
MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (02) :531-539
[5]  
GAO HK, 1994, CANCER RES, V54, P4342
[6]   P53 IN TUMOR PATHOLOGY - CAN WE TRUST IMMUNOHISTOCHEMISTRY - REVISITED [J].
HALL, PA ;
LANE, DP .
JOURNAL OF PATHOLOGY, 1994, 172 (01) :1-4
[7]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53
[8]  
Ikeda G, 1999, CANCER, V86, P1396, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1396::AID-CNCR3>3.0.CO
[9]  
2-H
[10]  
Kanamoto A, 1999, J SURG ONCOL, V72, P94, DOI 10.1002/(SICI)1096-9098(199910)72:2<94::AID-JSO10>3.3.CO